Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study.
Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study.
复制标题
DOI：
10.1093/cid/ciab172
复制
发表时间：
2021-12-16
期刊：
影响因子：
--
通讯作者：
van Binnendijk RS
中科院分区：
文献类型：
--
作者：
den Hartog G;Vos ERA;van den Hoogen LL;van Boven M;Schepp RM;Smits G;van Vliet J;Woudstra L;Wijmenga-Monsuur AJ;van Hagen CCE;Sanders EAM;de Melker HE;van der Klis FRM;van Binnendijk RS
评估感染严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）后的免疫持续时间是衡量感染后保护程度的首要任务。这种知识是缺乏的，特别是在普通人群中。在这里，我们研究了全国样本中sars - cov -2特异性血清抗体免疫球蛋白同型血清阳性和免疫球蛋白G （IgG）结合强度在症状出现后长达7个月的变化。根据IgG血清转化为SARS-CoV-2刺突S1蛋白（N = 353）纳入荷兰前瞻性代表性血液学研究的参与者（N = 738），每个血清转化的参与者最多连续3个血清样本。测定免疫球蛋白M （IgM）、免疫球蛋白A （IgA）和IgG抗体对S1的浓度，以及自疾病症状出现以来IgG贪婪度的增加与时间的关系。虽然sars - cov -2特异性IgM和IgA抗体在发病后第一个月迅速下降，但在7个月后，92%（95%可信区间[CI]， 89%-95%）的参与者仍存在特异性IgG。估计IgG抗体下降2倍为158天（95% CI， 136-189天）。与无症状者或仅有轻度上呼吸道主诉者相比，报告有明显症状者的浓度维持得更好。同样，与症状轻微或无症状者相比，有症状者的IgG抗体随时间的增加幅度更大（P = 0.022）。sars - cov -2特异性IgG抗体持续存在并随时间增加，表明潜在的免疫成熟。这些数据支持开发针对SARS-CoV-2的免疫记忆，从而深入了解对一般未接种疫苗的人群的保护。NL8473（荷兰试验登记）。在这个全国性的样本中，在出现SARS-CoV-2感染症状7个月后，92%的参与者体内仍存在免疫球蛋白（Ig） G抗体，而IgM和IgA抗体则减弱。有症状者浓度较高，并且随时间增加。
Assessing the duration of immunity following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a first priority to gauge the degree of protection following infection. Such knowledge is lacking, especially in the general population. Here, we studied changes in immunoglobulin isotype seropositivity and immunoglobulin G (IgG) binding strength of SARS-CoV-2–specific serum antibodies up to 7 months following onset of symptoms in a nationwide sample. Participants from a prospective representative serological study in the Netherlands were included based on IgG seroconversion to the spike S1 protein of SARS-CoV-2 (N = 353), with up to 3 consecutive serum samples per seroconverted participant (N = 738). Immunoglobulin M (IgM), immunoglobulin A (IgA), and IgG antibody concentrations to S1, and increase in IgG avidity in relation to time since onset of disease symptoms, were determined. While SARS-CoV-2–specific IgM and IgA antibodies declined rapidly after the first month after disease onset, specific IgG was still present in 92% (95% confidence interval [CI], 89%–95%) of the participants after 7 months. The estimated 2-fold decrease of IgG antibodies was 158 days (95% CI, 136–189 days). Concentrations were sustained better in persons reporting significant symptoms compared to asymptomatic persons or those with mild upper respiratory complaints only. Similarly, avidity of IgG antibodies for symptomatic persons showed a steeper increase over time compared with persons with mild or no symptoms (P = .022). SARS-CoV-2–specific IgG antibodies persist and show increasing avidity over time, indicative of underlying immune maturation. These data support development of immune memory against SARS-CoV-2, providing insight into protection of the general unvaccinated part of the population. NL8473 (the Dutch trial registry). In this nationwide sample, immunoglobulin (Ig) G antibodies were sustained in 92% of the participants after 7 months after onset of symptoms of SARS-CoV-2 infection, whereas IgM and IgA antibodies wane. Concentrations are higher in symptomatic persons and avidity increases with time.
登录
查看更多内容
DOI：
10.1093/infdis/jiaa483
发表时间：
2021-07-15
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Berbers G;Mollema L;van der Klis F;den Hartog G;Schepp R
通讯作者：
Schepp R
影响因子：
24.8
作者：
Isho B;Abe KT;Zuo M;Jamal AJ;Rathod B;Wang JH;Li Z;Chao G;Rojas OL;Bang YM;Pu A;Christie-Holmes N;Gervais C;Ceccarelli D;Samavarchi-Tehrani P;Guvenc F;Budylowski P;Li A;Paterson A;Yue FY;Marin LM;Caldwell L;Wrana JL;Colwill K;Sicheri F;Mubareka S;Gray-Owen SD;Drews SJ;Siqueira WL;Barrios-Rodiles M;Ostrowski M;Rini JM;Durocher Y;McGeer AJ;Gommerman JL;Gingras AC
通讯作者：
Gingras AC
影响因子：
3.7
作者：
Scherpenisse M;Schepp RM;Mollers M;Meijer CJ;Berbers GA;van der Klis FR
通讯作者：
van der Klis FR
影响因子：
158.5
作者：
Gudbjartsson, Daniel F.;Norddahl, Gudmundur L.;Stefansson, Kari
通讯作者：
Stefansson, Kari
影响因子：
16.6
作者：
Hammarlund E;Thomas A;Amanna IJ;Holden LA;Slayden OD;Park B;Gao L;Slifka MK
通讯作者：
Slifka MK